Circular Genomics Strengthens Scientific Advisory Board
Circular Genomics, a pioneer in circular RNA (circRNA) biomarkers dedicated to advancing neurology and psychiatry, has recently bolstered its Scientific Advisory Board (SAB) by welcoming Phyllis Barkman Ferrell, MBA, DrPH. With her extensive background in Alzheimer's disease and dementia research, Ferrell's appointment marks a significant enhancement for the company's mission to revolutionize methods of diagnosis and treatment in the psychiatric and neurological domains.
Welcoming a New Expertise
Phyllis Ferrell is a well-respected figure in the field of neurological conditions with a primary focus on Alzheimer's disease (AD). Her vast experience offers a valuable resource for Circular Genomics, which strives to innovate in the fields of psychiatric and neurological health. According to Nikolaos Mellios, MD, PhD, Chief Scientific Officer of Circular Genomics, "Her deep experience in AD research will be invaluable as we continue to explore innovative solutions for early and accurate diagnosis and treatment of this devastating disease that affects millions of people across the world." These sentiments highlight the critical nature of Ferrell's role in enhancing the company’s scientific approach.
Compelling Experience and Contributions
Phyllis Ferrell comes with a robust background advocating for advances in AD and cognitive impairment. She has played pivotal roles in various esteemed organizations committed to enhancing AD research, such as the Davos Alzheimer Collaborative and the Alzheimer's Drug Discovery Foundation. Her leadership experience extends to significant roles at Eli Lilly & Company, where she was the Global Head of External Engagement for AD for nearly a decade.
Ferrell emphasizes her dedication to improving brain health, stating, "As a passionate advocate for brain health – driven by my own personal experience in my family – it is important for individuals to better understand their mental and brain health to find optimal treatments." This perspective resonates with Circular Genomics' goal of advancing diagnostic techniques and treatments for AD.
Building a Dedicated Advisory Board
Dr. Ferrell joins a distinguished team of experts on the Circular Genomics SAB, which includes several highly regarded leaders in the fields of neurology, psychiatry, and precision medicine. Notable members of the board include:
- Roy Perlis, MD: Director, Center of Experimental Drugs & Diagnostics at Massachusetts General Hospital.
- Madhukar Trivedi, MD: Chief of the Division of Mood Disorders at UT Southwestern Medical Center.
- Carlos Cruchaga, PhD: Professor of Psychiatry and Neurology at Washington University School of Medicine.
- Eleni Tzavara, MD, PhD: Research Director of Translational Psychopharmacology.
- Nikolaos Daskalakis, MD, PhD: Director of the Neurogenomics and Translational Bioinformatics Laboratory.
- Mike Ackerman, MD, PhD: Co-Founder and CBO of Arrivo Bioventures.
About Circular Genomics
Circular Genomics is the leading innovator in developing circular RNA-based precision medicine tools designed for the treatment of psychiatric and neurological conditions. The company utilizes exclusive licenses and groundbreaking technologies to redefine treatment approaches for major depressive disorder, working diligently to tailor optimal treatment protocols that greatly shorten the timeline for validating treatment effectiveness.
By advancing circRNA biomarker research, Circular Genomics is positioned at the forefront of scientific exploration, working towards better understanding and management of complex conditions such as Alzheimer's disease. Their initial offerings include comprehensive assays that enable rapid assessment and personalized treatment methodologies.
Frequently Asked Questions
What is Circular Genomics known for?
Circular Genomics focuses on developing circular RNA-based precision medicine tools and diagnostics aimed at enhancing outcomes in neurology and psychiatry.
Why is Phyllis Ferrell's appointment significant?
Her extensive background in Alzheimer's research will provide critical insights into innovative diagnostic and treatment approaches for neurological health.
What is the goal of Circular Genomics?
The primary goal is to improve the diagnosis and treatment of psychiatric and neurological disorders using advanced circular RNA biomarkers.
Who else is on the Scientific Advisory Board?
The board includes renowned experts such as Roy Perlis, Madhukar Trivedi, Carlos Cruchaga, and others, contributing a wealth of knowledge and experience.
How does Circular Genomics tailor treatment protocols?
By leveraging circRNA biomarker research, the company aims to rapidly assess and individualize treatment plans based on patient-specific data.
